✓ Revise Right course
Monoclonal antibodies are identical antibodies produced from a single clone of cells, specific to one binding site. Free notes and 13 questions answered.
What are monoclonal antibodies and their key properties is part of Monoclonal antibodies (biology only) (HT only) in GCSE AQA Higher Biology.
4 min
Reading time
17
Lessons in this topic
GCSE AQA Higher
Pathway
Reviewed by Revise Right
Content review
Monoclonal antibodies are identical antibodies produced from a single clone of cells, specific to one binding site. Free notes and 13 questions answered.
AQA GCSE Biology mock draft, 26–31 Oct. Draft coverage: Biology Paper 1 (Higher tier). Reviewed for an original-practice sitting; check student availability before registering. Marking and results will follow later, after separate approval. Eligible new accounts receive a five-day Pro trial when signup email verification completes. Previous trials keep their original expiry. After expiry, new papers need Pro unless you have an explicitly confirmed free sitting offer for this event. That offer adds no Pro time or AI learning. Saved attempts and released results remain readable. No card or automatic charge.
Use this lesson to stay inside Monoclonal antibodies (biology only) (HT only) while connecting the detail back to the wider Infection and response topic.
Read the core explanations from What are monoclonal antibodies and their key properties before testing yourself from memory.
Your immune system produces thousands of different antibodies when fighting infection. Each B-lymphocyte makes its own unique antibody. But what if we could mass-produce identical copies of just one perfect antibody?
That's exactly what monoclonal antibodies are - identical antibodies produced from a single clone of cells. Think of them as precision-guided missiles that target one specific enemy, rather than a shotgun blast hitting everything nearby.
Trap: Many students think monoclonal antibodies can bind to multiple different antigens. Actually, each monoclonal antibody is specific to just one binding site on one protein antigen - that's what makes them so useful for precise targeting.
Creating monoclonal antibodies involves solving a tricky problem. B-lymphocytes make great antibodies but die quickly in culture. Tumour cells live forever but don't make antibodies. The solution? Fuse them together.
Worked example: Production of Monoclonal Antibodies
Describe the process of producing monoclonal antibodies from start to finish.
Answer: Monoclonal antibodies are produced by fusing B-lymphocytes with tumour cells to create hybridoma cells that can produce specific antibodies indefinitely.
This process is brilliant because it solves two problems at once. The B-lymphocyte provides the genetic instructions for making the specific antibody we want. The tumour cell provides the ability to divide indefinitely, giving us a renewable source of identical antibodies.
The key property that makes monoclonal antibodies so useful is their incredible specificity. Each monoclonal antibody binds to just one binding site on one protein antigen - like a key that fits only one lock.
This specificity comes from the antibody's shape. The variable region of each antibody has a unique 3D structure that perfectly complements the shape of its target antigen. It's like molecular recognition - the antibody 'recognises' its specific target among millions of other molecules.
Because monoclonal antibodies come from a single clone of cells, they're all identical. This means every single antibody molecule has exactly the same specificity - they all target the same binding site on the same antigen.
Understanding the difference between monoclonal antibodies and your body's normal immune response helps explain why monoclonal antibodies are so valuable in medicine.
When your immune system encounters an antigen, it produces polyclonal antibodies - many different antibodies from many different B-lymphocytes. Each B-lymphocyte recognises a different part of the same antigen, creating a diverse mixture of antibodies.
Monoclonal antibodies are the opposite - they're all identical copies targeting exactly the same binding site. This gives them unique advantages for medical applications where precision is crucial.
The ability to target specific chemicals or specific cells makes monoclonal antibodies incredibly powerful medical tools. They can be designed to seek out and bind to almost any target in the body with laser-like precision.
For example, cancer cells often have unique proteins on their surface that healthy cells don't have. Monoclonal antibodies can be designed to recognise these cancer-specific proteins, allowing them to target cancer cells while leaving healthy cells alone.
This targeting ability extends beyond just binding. Monoclonal antibodies can be linked to drugs, radioactive substances, or toxins. The antibody acts like a guided missile, delivering its payload directly to the target cells.
Exam questions about monoclonal antibodies often test your understanding of the production process and the concept of specificity. Here's how to tackle them successfully.
Common exam mistakes to avoid:
• Saying monoclonal antibodies can bind to 'many different antigens' - they're specific to just one binding site
• Forgetting to mention the fusion step in production - this is crucial for creating hybridoma cells
• Confusing B-lymphocytes with other immune cells - it's specifically B-lymphocytes that produce antibodies
Published by Revise Right. Use the official specification reference to check the requirements for your course. Content updated: 2026-03-20.
Move to the related lessons or back to the topic page when you need the wider sequence before exam-style practice.
Monoclonal antibodies are identical antibodies produced from a single clone of cells that are specific to one binding site on one protein antigen. Because of this, they can be used to target specific chemicals or specific cells in the body.
Polyclonal antibodies are the many different antibodies made by many different B-lymphocytes during a normal immune response, each recognising a different part of the same antigen. Monoclonal antibodies are all identical copies targeting exactly the same binding site, which gives them precision for medical applications.
B-lymphocytes produce antibodies, with each B-lymphocyte making its own unique antibody. To make monoclonal antibodies, B-lymphocytes from a mouse's spleen are fused with tumour cells, because B-lymphocytes die quickly in culture while tumour cells divide indefinitely.
Monoclonal means produced from a single clone of cells. Monoclonal antibodies are identical antibodies made by one clone, so every antibody molecule has exactly the same specificity and targets the same binding site on the same antigen.
Monoclonal antibodies are specific because the variable region of each antibody has a unique 3D structure that complements the shape of its target antigen, like a key that fits only one lock. Since they come from a single clone of cells, every antibody molecule targets the same binding site on the same antigen.
Antigen specificity is the property that lets an antibody bind to only one specific binding site on one particular antigen. It is determined by the complementary shape between antibody and antigen: the variable region of each antibody has a unique 3D structure that fits its target.
Cancer cells often have unique proteins on their surface that healthy cells do not have, and monoclonal antibodies can be designed to recognise these proteins, targeting cancer cells while leaving healthy cells alone. They can also be linked to drugs, radioactive substances or toxins to deliver them directly to the target cells.
A monoclonal antibody cannot bind to many different antigens; each one is specific to just one binding site on one protein antigen. This specificity, like a key that fits only one lock, is what makes monoclonal antibodies so useful for precise targeting.
B-lymphocytes are fused with tumour cells because B-lymphocytes make the specific antibody wanted but die quickly in culture, while tumour cells divide indefinitely but do not make antibodies. The fused hybridoma cell does both, giving a renewable source of identical antibodies.
A mouse is injected with the specific antigen to stimulate its immune system to produce B-lymphocytes that make the desired antibody. These activated B-lymphocytes are then removed from the mouse's spleen and fused with tumour cells.
Unfused cells are removed by growing the cells in a selective culture medium, where only hybridoma cells survive. Unfused B-lymphocytes die, and unfused tumour cells cannot survive the selective medium.
Monoclonal antibodies can target cancer cells because cancer cells often have unique proteins on their surface that healthy cells do not have. Antibodies designed to recognise these proteins bind to cancer cells and leave healthy cells alone, and can carry drugs, radioactive substances or toxins to them.
Common mistakes about monoclonal antibodies are saying they can bind to many different antigens, forgetting the fusion step that creates hybridoma cells, and confusing B-lymphocytes with other immune cells. It is specifically B-lymphocytes that produce antibodies.